Results for tag: "Focal Segmental Glomerulosclerosis"

Focal Segmental Glomerulosclerosis (FSGS) is a type of kidney disorder that affects the filtering units of the kidney, known as glomeruli. It is a leading cause of nephrotic syndrome, a condition characterized by proteinuria, edema, and hypoalbuminemia. FSGS is a major cause of end-stage renal disease (ESRD) and is associated with a high risk of progression to ESRD. Treatment of FSGS is focused on controlling the underlying cause, if possible, and managing the symptoms. Treatment options include medications, lifestyle modifications, and dialysis. The market for Liver and Kidney Disorders Drugs is expected to grow in the coming years due to the increasing prevalence of chronic kidney diseases and liver diseases. The market is driven by factors such as the increasing prevalence of diabetes, rising geriatric population, and the increasing demand for organ transplants. Companies in the Focal Segmental Glomerulosclerosis market include AstraZeneca, GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Novartis. Show Less Read more